L2A5 antibody or functional fragment thereof against tumour antigens
US11353460B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 17, 2019 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | May 27, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides an antibody or functional antibody fragments, or probe thereof directed against a unique group of antigens identified in cancer.The present invention comprises nucleotide sequences derived from L2A5 monoclonal antibody. The antibody or functional antibody fragment, or probe thereof includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. This DNA/amino acid sequence conjugation is unique and has never been described before. The present invention further provides antibody or functional antibody fragment or a conjugate or a recombinant protein useful in the detection, treatment and prevention of human disease, including cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.